Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + osimertinib + pemetrexed
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination regimen consisting of three drugs—cisplatin, osimertinib, and pemetrexed—used in the treatment of certain cancers, most notably non-small cell lung cancer (NSCLC). Each component has a distinct mechanism of action: - Cisplatin is a platinum-based chemotherapy agent that causes DNA crosslinking and damage, leading to apoptosis in rapidly dividing cells. - Osimertinib is an oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that selectively targets both EGFR-sensitizing and T790M resistance mutations. - Pemetrexed is an antifolate antineoplastic agent that inhibits multiple folate-dependent enzymes involved in the synthesis of DNA and RNA, thereby blocking cancer cell replication[1][2][3][4][5]. This combination may be used for advanced or metastatic NSCLC with specific molecular profiles or as part of clinical trials.
- Brand names
- Tagrisso + Alimta + Platinol
- Other names
- osimertinib + pemetrexed + cisplatinTagrisso + Alimta + Platinolosimertinib + cisplatin + pemetrexed
02
Targets
GART (GAR transformylase)TS (Thymidylate synthase)DNADHFR (Dihydrofolate reductase)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on cisplatin + osimertinib + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + osimertinib + pemetrexed.